Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.

Kevin M. Campbell,Susan Groshen,Araz Marachelian,Sharmistha Pal,Daphne A. Haas-Kogan,Mark D. Kellogg,Angela C. Evans,Matthew A. Coleman,Julie R. Park,Meaghan Granger,Katherine K. Matthay,Steven G. DuBois

Journal of Clinical Oncology（2020）

引用 0|浏览1

暂无评分

摘要

e22514Background: 131I-metaiodobenzylguanidine (MIBG), a radiopharmaceutical agent, has demonstrated efficacy as a single agent for patients with neuroblastoma. Recently, trials have focused on MIB...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要